Auropharmas API facility gets EIR from USFDA

17 Nov 2022 , 10:06 AM

The drug maker announced the receipt of an Establishment Inspection Report (EIR) from the USFDA for its API non-antibiotic manufacturing facility in Pydibhimavaram, Srikakulam District, Andhra Pradesh. The US drug regulator had inspected the facility in February 2019 and issued a warning letter in June 2019 and this unit was further inspected by USFDA from 25 July to 2 August 2022 and issued a form 483 with 3 observations. The USFDA has indicated that the inspection is closed. Aurobindo Pharma develops, manufactures and distributes generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients. The pharmaceutical company reported 32.4% fall in consolidated net profit to Rs 520.5 crore in Q1 FY23 from Rs 770 crore in Q1 FY22. Revenue from operations increased 9.4% YoY to Rs 6,235.9 crore in Q1 FY23. The scrip rose 0.21% to currently trade at Rs 479.10 on the BSE. Powered by Capital Market – Live News